Correction to: HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study

E. Viscusi¹ · H. Minkowitz² · P. Winkle³ · S. Ramamoorthy⁴ · J. Hu⁵ · N. Singla⁶

Published online: 4 February 2020

© Springer-Verlag France SAS, part of Springer Nature 2020

Correction to: Hernia (2019) 23:1071–1080

<https://doi.org/10.1007/s10029-019-02023-6>

In Abstract, under the section “Results”, the first and third p values are incorrect. The correct p values should be $p=0.0004$ and $p<0.0001$ respectively.

In Results, under the section “Efficacy” and sub-section “Primary and secondary endpoints”, the p value in the first sentence of the second paragraph is incorrect. The correct p value should be $p=0.0004$.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s10029-019-02023-6>.

✉ E. Viscusi
Eugene.Viscusi@jefferson.edu

¹ Sidney Kimmel Medical College of Thomas Jefferson University, 111 South 11th Street, Gibbon Building, Suite 8490, Philadelphia, PA 19107, USA

² HD Research Corp, Houston, TX, USA

³ Anaheim Clinical Trials, Anaheim, CA, USA

⁴ University of California at San Diego Health System, San Diego, CA, USA

⁵ Heron Therapeutics, Inc., San Diego, CA, USA

⁶ Lotus Clinical Research, LLC, Pasadena, CA, USA